Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (6.940.517 €): CAR-engineered Cell therapy for Cardiovascular diseases Hor 01.10.2026 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
CAR-engineered Cell therapy for Cardiovascular diseases
CARDIO will develop a next-generation immunotherapy based on gene-engineered regulatory T cells (Tregs) to restore immune homeostasis during acute and chronic inflammation in cardiovascular disease. Myocardial infarction (MI), often caused by atherosclerosis (AS), is a leading cause of death in Europe—affecting one in seven women and one in six men. MI results from thrombotic occlusion following plaque rupture or erosion, leading to myocardial ischemia, cell death, and a self-perpetuating inflammatory response. This unresolved inflammation impairs tissue repair, drives adverse remodeling, and contributes to both acute and chronic heart failure (HF), with devastating impacts on patient quality of life and survival. Given the heart’s negligible regenerative capacity, CARDIO will utilize Tregs to (i) suppress chronic inflammation within atherosclerotic plaques, preventing their rupture, and (ii) disrupt the acute inflammatory cycle post-MI to support myocardial healing. CARDIO Tregs will be derived from healthy donors as an allogeneic, virus-free gene-engineered “off-the-shelf” product. To enhance specificity and function, they will be equipped with chimeric antigen receptors (CARs) targeting myocardial (MYOCAR) and atherosclerotic (ASCAR) antigens. Upon antigen recognition, these CAR Tregs will secrete tolerogenic cytokines and suppress inflammatory macrophages and T cells—key drivers of fibrosis and plaque progression. Using in vivo CRISPR screening and protein engineering, CARDIO will tailor Tregs to inflammatory niches, ensuring stability and effective immune modulation. The ultimate goal is to deliver the first cellular immunotherapy for reducing atheroprogression and improving post-MI recovery—transforming outcomes for patients and reducing cardiovascular mortality.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Bayerische Forschungsallianz Bavarian Research Alliance GmbH | 191.973 € |
| Cemm - Forschungszentrum Fuer Molekulare Medizin GmbH | 1.348.444 € |
| Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) | 526.661 € |
| DKMS Group gGmbH | 121.562 € |
| T-Curx GmbH | 1.046.000 € |
| Universitaet Fuer Bodenkultur Wien | 1.132.100 € |
| Universitaetsklinikum Wuerzburg - Klinikum DER Bayerischen Julius-Maximilians-Universitat | 2.573.777 € |
Quelle: https://cordis.europa.eu/project/id/101289864
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.